ADNI is a global research effort that actively supports the investigation and development of treatments that slow or stop the progression of AD. This multisite, longitudinal study assesses clinical, imaging, genetic and biospecimen biomarkers through the process of normal aging to early mild cognitive impairment (EMCI), to late mild cognitive impairment (LMCI), to dementia or AD. With established, standardized methods for imaging and biomarker collection and analysis, ADNI facilitates a way for scientists to conduct cohesive research and share compatible data with other researchers around the world.
The ADNI study has three phases: ADNI1, ADNI GO and ADNI2. New participants were recruited across North America during each phase of the study and agreed to complete a variety of imaging and clinical assessments. Participants are followed and reassessed over time to track the pathology of the disease as it progresses. Results are then shared by ADNI through USC’s Laboratory of Neuro Imaging’s Image Data Archive (IDA).
The table below summarizes the North American ADNI study target participant numbers, as well as the types of data taken at the different phases. In reality, the total number of study participants vary.
The overall goal of ADNI is to validate biomarkers for use in Alzheimer’s disease clincal treatment trials. ADNI is not a population based study and enrolls selected populations who may be used in future treatment trials. Therefore the results from ADNI may not be generalizable to other populations
Become a Study Participant
If you are interested in participating in ADNI as a study volunteer, please visit the Alzheimer’s Disease Education and Referral (ADEAR) Center Website. 50 ADNI Clinical Trial Sites are located across the US and Canada. Recruitment for ADNI GO began February 2010 and will continue to December 2012 or until it is fulfilled. ADNI 2 is recruiting.